Back

prof. dr. E.E. Voest

prof. dr. E.E. Voest

Full Professor
prof. dr. E.E. Voest
  • Department of Medical Oncology

Research Programs

Strategic Program Cancer

Biography

Biography

Emile Voest is professor of Medical Oncology, senior group leader at the Netherlands Cancer Institute, senior scientist of the Oncode Institute, and translational scientist. He is the current chair of the board of directors of Cancer Core Europe, a collaboration of 7 excellent comprehensive cancer centers. Until 2021, he served as executive medical director of the Netherlands Cancer Institute. He is also an independent, non-executive board member of Sanofi, is co-founder and serves on the non-executive board of the Hartwig Medical Foundation. He recently has co-founded Mosaic Therapeutics, devoted to developing new combinatorial treatments in a specific genomic background.

 

His academic group is devoted to bringing precision medicine to patients and is focused on large scale genomic sequencing of patients with metastatic cancer, the development of co-culture models of primary cultures of tumors (i.c. organoids) and immune cells to improve drug development and immunotherapy and to determine which treatment is best for a specific patient via computational, integrated approaches.

Side Activities

1999-   Professor of Medical Oncology, University of Utrecht, University Medical Center, Utrecht (UP)

2010-   Chair of the Scientific Advisory Board of InteRNA (PtP)

2013-   Editorial board of Clinical Cancer Research (UP)

2015-   Editorial board of JAMA Oncology (UP)

2015-   Member of supervisory board Hartwig Medical Foundation (UP)

2016-   Editorial board ESMO Open, Cancer Horizons (UP)

2016-   Executive Board of Cancer Core Europe (UP)

2016-   Advisor Biogeneration Ventures (PtP)

2019-   Senior Group Leader of the Oncode Institute (UP)

2019-   Advisor of Agalia Venture Capital (UP)

2019-   Managing director, Executive Board of Directors, Cancer Core Europe (UP)

2020-2022   Advisor Frame Therapeutics (UP)

2021-   Scientific Advisory Committee (SAC) for Omico (trading as the Australian Genomic Cancer Medicine Centre (AGCMC) (UP)

2021-   Clinical Advisory Board Cambridge Cancer Center, UK (UP)

2021-   Scientific Advisory Board Institute Gustave Roussy, Paris, France (PtP)

2021-   Scientific Advisory Board GROW Oncology, Maastricht, Netherlands (UP)

2022-   Independent, non-executive board member Sanofi, Paris, France (PtP)

2022-   Co-founder Mosaic Therapeutics, Cambridge, UK (PtP)

2022-   Board member Center for Personalized Cancer Treatment (UP)

UP=unpaid
PtP= paid to person

Research Output (298)

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

Geurts Birgit S, Battaglia Thomas W, van Berge Henegouwen J Maxime, Zeverijn Laurien J, de Wit Gijs F, Hoes Louisa R, van der Wijngaart Hanneke, van der Noort Vincent, Roepman Paul, de Leng Wendy W J, Jansen Anne M L, Opdam Frans L, de Jonge Maja J A, Cirkel Geert A, Labots Mariette, Hoeben Ann, Kerver Emile D, Bins Adriaan D, Erdkamp Frans G L, van Rooijen Johan M, Houtsma Danny, Hendriks Mathijs P, de Groot Jan-Willem B, Verheul Henk M W, Gelderblom Hans, Voest Emile E Dec 2023, In: BMC Cancer. 23

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics

Schipper L. J., Samsom K. G., Snaebjornsson P., Battaglia T., Bosch L. J.W., Lalezari F., Priestley P., Shale C., van den Broek A. J., Jacobs N., Roepman P., van der Hoeven J. J.M., Steeghs N., Vollebergh M. A., Marchetti S., Cuppen E., Meijer G. A., Voest E. E., Monkhorst K. Dec 2022, In: ESMO open. 7

Can Drug Repurposing Accelerate Precision Oncology?

Schipper Luuk J., Zeverijn Laurien J., Garnett Mathew J., Voest Emile E. 1 Jul 2022, In: Cancer Discovery. 12 , p. 1634-1641 8 p.

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells

Zhang Zhengkui, Kong Xiangjun, Ligtenberg Maarten A., van Hal-van Veen Susan E., Visser Nils L., de Bruijn Beaunelle, Stecker Kelly, van der Helm Pim W., Kuilman Thomas, Hoefsmit Esmée P., Vredevoogd David W., Apriamashvili Georgi, Baars Beau, Voest Emile E., Klarenbeek Sjoerd, Altelaar Maarten, Peeper Daniel S. 21 Jun 2022, In: Cell Reports Medicine. 3 , p. 1-25

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer

van Berge Henegouwen J M, Jebbink M, Hoes L R, van der Wijngaart H, Zeverijn L J, van der Velden D L, Roepman P, de Leng W W J, Jansen A M L, van Werkhoven E, van der Noort V, van der Wekken A J, de Langen A J, Voest E E, Verheul H M W, Smit E F, Gelderblom H 15 Jun 2022, In: European Journal of Cancer. 171 , p. 114-123 10 p.

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach

Mulder Jorn, van Stuijvenberg Odile C., van Hennik Paula B., Voest Emile E., Pasmooij Anna M.G., Stoyanova-Beninska Violeta, de Boer Anthonius 14 Jun 2022, In: Frontiers in medicine. 9 , p. 1-12

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer:a case series and review of literature

van Berge Henegouwen J M, van der Wijngaart H, Zeverijn L J, Hoes L R, Meertens M, Huitema A D R, Devriese L A, Labots M, Verheul H M W, Voest E E, Gelderblom H 22 May 2022, In: Cancer Chemotherapy and Pharmacology. 90 , p. 97-104 8 p.

Author Correction:The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

Tamborero David, Dienstmann Rodrigo, Rachid Maan Haj, Boekel Jorrit, Lopez-Fernandez Adria, Jonsson Markus, Razzak Ali, Braña Irene, De Petris Luigi, Yachnin Jeffrey, Baird Richard, Loriot Yohann, Massard Christophe, Martin-Romano Patricia, Opdam Frans, Schlenk Richard F., Vernieri Claudio, Masucci Michele, Villalobos Xenia, Chavarria Elena, Anand Shubha, Baars Danny, Bajalica-Lagercrantz Svetlana, Baird Richard, Bierkens Mariska, Blomqvist Lennart, Bono Costanza, De Petris Luigi, Doherty Gary J., Forest Arnauld, Fornerone Valentina, Gabaldi Paola, Haglund Felix, Hartman Johan, Horak Peter, Jutzi Tanja, Kasanicki Mary, Kreutzfeldt Simon, Le Cornet Lucian, Lewensohn Rolf, Lindberg Johan, Lopez Carlos, Lundqvist Andreas, Martin Jose Ezequiel, Meijer Gerrit, Muñoz Susana, Camus Maud Ngo, Nicotra Claudio, Nuciforo Paolo, Voest Emile, May 2022, In: Nature Cancer. 3 , p. 649-649 1 p.

The DRUG Access Protocol:access inequality and European harmonisation – Authors' reply

van Waalwijk van Doorn-Khosrovani Sahar Barjesteh, Zeverijn Laurien J., Voest Emile E. May 2022, In: The Lancet Oncology. 23 , p. e203-e203 1 p.

Delivering precision oncology to patients with cancer

Mateo Joaquin, Steuten Lotte, Aftimos Philippe, André Fabrice, Davies Mark, Garralda Elena, Geissler Jan, Husereau Don, Martinez-Lopez Iciar, Normanno Nicola, Reis-Filho Jorge S., Stefani Stephen, Thomas David M., Westphalen C. Benedikt, Voest Emile Apr 2022, In: Nature Medicine. 28 , p. 658-665 8 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet